A Biomarker Screening Protocol for Participants With Solid Tumors

TerminatedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

May 19, 2023

Primary Completion Date

February 5, 2025

Study Completion Date

February 5, 2025

Conditions
Triple Negative Breast CancerNon-small Cell Lung CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-Small Cell Carcinoma of Lung, TNM Stage 4Advanced Breast CancerAdvanced Lung CarcinomaNSCLCNSCLC, RecurrentNSCLC Stage IVRelapsed CancerRelapse/RecurrenceRecurrent Breast CancerRecurrent NSCLCPlatinum-resistant Ovarian CancerOvarian CancerPrimary Peritoneal CarcinomaFallopian Tube CancerEndometrial CancerEndometrioid TumorHigh Grade Serous CarcinomaOvarian Epithelial Cancer
Trial Locations (1)

27804

Accellacare, Rocky Mount

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Lyell Immunopharma, Inc.

INDUSTRY